Medical Condition News

RSS

Merck Serono, EMD Serono resume Stimuvax clinical program for NSCLC

Merck Serono, a division of Merck KGaA, and its U.S. affiliate, EMD Serono, Inc. today announced that they are resuming their Stimuvax® (BLP25 liposome vaccine) clinical program in patients with non-small cell lung cancer (NSCLC) which includes the Phase III studies, STARTa and INSPIREb. The treatment and enrollment in these studies will restart after approval by the local regulatory authorities and ethics committees.

17 Jun 2010

New study shows 72% of women with RA suffer pain daily

Almost three quarters (72%) of women with Rheumatoid Arthritis suffer pain daily, despite the fact that three quarters (75%) receive pain relief medication, according to a new study presented today at EULAR 2010, the Annual Congress of the European League Against Rheumatism in Rome, Italy. Furthermore the physical pain appears to affect women to such an extent that it impacts negatively on emotional and social aspects of their lives.

17 Jun 2010

Xacore signs agreement with ESSE to tackle challenge of military hearing loss

Xacore announces today that they have entered into an agreement with Ellis Services and Solutions Enterprises, LLC headed by retired US Army Four-Star General Larry R. Ellis and his group of experienced professionals to tackle the challenge of military hearing loss. This agreement joins Xacore's leading edge noise protection DSP radio headset technology with the strengths of ESSE's experience in marketing and solutions with the military and government.

17 Jun 2010

QR Pharma, Massachusetts General Hospital announce Parkinson's disease research collaboration

QR Pharma, Inc. (QR) and Massachusetts General Hospital announced today a new collaborative research agreement to work on a treatment for Parkinson's disease (PD).

17 Jun 2010

Gamma-Dynacare to implement SQI's SQiDworks diagnostics platform

SQI Diagnostics Inc., a medical systems company focused on evolving laboratory-based biomarker testing, today announced that Gamma-Dynacare Medical Laboratories, one of Canada's largest providers of laboratory services, has agreed to put into operation SQI's SQiDworks(TM) platform, and to purchase SQI's multiplexed IgXplex(TM) Rheumatoid Arthritis consumables to meet its commercial needs.

17 Jun 2010

Curis reports topline results from GDC-0449 Phase II clinical trial for metastatic colorectal cancer

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced topline results from a Phase II clinical trial conducted by Roche and Genentech, Curis' collaborator and a wholly owned member of the Roche Group, of GDC-0449, a first-in-class Hedgehog pathway inhibitor. GDC-0449 was tested in combination with Avastin® (bevacizumab) and FOLFOX or FOLFIRI chemotherapy in first-line metastatic colorectal cancer patients.

17 Jun 2010

Smokeless tobacco affects normal function of CYP-450 family of enzymes: Report

Far from having adverse effects limited to the mouth, smokeless tobacco affects the normal function of a key family of enzymes found in almost every organ in the body, according to the first report on the topic in ACS' monthly journal Chemical Research in Toxicology. The enzymes play important roles in production of hormones, including the sex hormones estrogen and testosterone; production of cholesterol and vitamin D; and help the body breakdown prescription drugs and potentially toxic substances.

17 Jun 2010

LCA commends Senator John Kerry for backing Lung Cancer Mortality Reduction Act

Today, Lung Cancer Alliance commended Senator John Kerry (D-MA) for backing the Lung Cancer Mortality Reduction Act, S.332. This is the first ever authorizing legislation that establishes a multi-agency, comprehensive program targeted at lung cancer.

17 Jun 2010

UF doctors administer newly available therapy for late-onset Pompe disease

The first commercially available treatment in the United States for patients with late-onset Pompe disease was administered today (Wednesday, June 16) at the University of Florida.

17 Jun 2010

IRX Therapeutics raises $8M to further develop pipeline of cancer vaccine candidates

IRX Therapeutics, a developer of novel immunomodulators to treat cancer and viral diseases, today announced that it has raised $8 million through a note offering to existing shareholders. The new funding will be used to further develop its pipeline of cancer vaccine candidates, including its lead product, IRX-2. IRX Therapeutics has now raised a total of more than $80 million in private financing.

17 Jun 2010

FDA approves clinical testing of SanBio's SB623 for stroke recovery

SanBio Inc. announced today that the United States Food and Drug Administration (FDA) has approved the clinical testing of their SB623 regenerative medicine product in patients suffering from disability caused by cerebral stroke. SB623 is derived from bone marrow stromal cells (MSCs) isolated from healthy adult donors.

17 Jun 2010

Alcohol consumption associated with reduced risk of developing several arthritic conditions: Study

Alcohol consumption is associated with a significantly reduced risk of developing several arthritic conditions including Rheumatoid Arthritis, Osteoarthritis, reactive arthritis, psoriatic arthritis and spondylarthropathy, according to results of a new study presented today at EULAR 2010, the Annual Congress of the European League Against Rheumatism in Rome, Italy.

17 Jun 2010

AGA Medical commences enrollment in AMPLATZER Cardiac Plug clinical trial

AGA Medical Holdings, Inc. today announced first patient enrollment in the feasibility phase of the prospective, multicenter, randomized AMPLATZER® Cardiac Plug clinical trial. Dr. William Nicholson, an interventional cardiologist and structural heart specialist at York Hospital in Pennsylvania, enrolled the first patient.

16 Jun 2010

Fortis International Oncology Centre equipped with Varian's advanced radiotherapy equipment

The first in a planned series of new radiotherapy centers aimed at improving access to advanced treatments for millions of Indian cancer patients has been officially opened in Noida. Fortis International Oncology Centre, a joint initiative between International Oncology and Fortis Healthcare, is equipped with advanced radiotherapy equipment and software from Varian Medical Systems.

16 Jun 2010

USPTO issues patent covering Probuphine for opiate addiction

Titan Pharmaceuticals, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued patent number 7,736,665 covering Probuphine for the treatment of opiate addiction.

16 Jun 2010

Dietary guideline on sodium puts Americans at risk

The Dietary Guidelines Advisory Committee (DGAC) of the U.S. Department of Health and Human Services and the U.S. Department of Agriculture may increase health risks, including obesity, by ignoring sound science as they announce recommendations to reduce sodium consumption to 1,500 mg per day, says the Salt Institute.

16 Jun 2010

Management of cardiovascular risk associated with insulin resistance, diabetes, and the metabolic syndrome

Adi Mehta, MD stresses the growing severity of the metabolic syndrome in the May 2010 edition of Postgraduate Medicine. Metabolic syndrome often leads to cardiovascular disease (CVD) because of its key components: diabetes, dyslipidemia, and hypertension. With obesity maintaining its status as a huge problem worldwide, physicians must act as soon as possible when they recognize metabolic syndrome or any of its components.

16 Jun 2010

New perspectives in type 2 diabetes, cardiovascular risk, and treatment goals

An article published in the May 2010 issue of Postgraduate Medicine highlights the seriousness of cardiovascular disease (CVD) in patients with type 2 diabetes. Cardiovascular disease is the cause of death in > 65% of patients with diabetes, and when complicated by the presence of obesity, the lifetime risk of developing CVD increases to 90%. The inherent problem is that many of the antihyperglycemic medications used to combat high glycated hemoglobin are associated with weight gain and/or hypoglycemia, which negatively affect CVD.

16 Jun 2010

A review of the response to oral anti-diabetes agents in patients with type 2 diabetes

Patients with type 2 diabetes show a progressive decline in glycemic control and receive antidiabetic therapy in order to reach the target glycated hemoglobin level of < 7% set by the American Diabetes Association and the European Association for the Study of Diabetes. An article published in the May 2010 issue of Postgraduate Medicine reviews the effectiveness of oral antidiabetes (OAD) agents in maintaining glycemic control in patients with type 2 diabetes.

16 Jun 2010

How to obtain appropriate type 2 diabetes control in the first 180 days of treatment initiation

Type 2 diabetes is characterized by unsatisfactory levels of glycated hemoglobin (HbA1c) for extended periods. An article published in the May 2010 edition of Postgraduate Medicine reports a proposal to shorten the total time spent with uncontrolled hyperglycemia by minimizing the number of steps along the treatment-intensification ladder. In doing so, patients would decrease their exposure to hyperglycemia and potentially improve long-term outcomes.

16 Jun 2010

Medical Condition News

Merck Serono, EMD Serono resume Stimuvax clinical program for NSCLC

New study shows 72% of women with RA suffer pain daily

Xacore signs agreement with ESSE to tackle challenge of military hearing loss

QR Pharma, Massachusetts General Hospital announce Parkinson's disease research collaboration

Gamma-Dynacare to implement SQI's SQiDworks diagnostics platform

Curis reports topline results from GDC-0449 Phase II clinical trial for metastatic colorectal cancer

Smokeless tobacco affects normal function of CYP-450 family of enzymes: Report

LCA commends Senator John Kerry for backing Lung Cancer Mortality Reduction Act

UF doctors administer newly available therapy for late-onset Pompe disease

IRX Therapeutics raises $8M to further develop pipeline of cancer vaccine candidates

FDA approves clinical testing of SanBio's SB623 for stroke recovery

Alcohol consumption associated with reduced risk of developing several arthritic conditions: Study

AGA Medical commences enrollment in AMPLATZER Cardiac Plug clinical trial

Fortis International Oncology Centre equipped with Varian's advanced radiotherapy equipment

USPTO issues patent covering Probuphine for opiate addiction

Dietary guideline on sodium puts Americans at risk

Management of cardiovascular risk associated with insulin resistance, diabetes, and the metabolic syndrome

New perspectives in type 2 diabetes, cardiovascular risk, and treatment goals

A review of the response to oral anti-diabetes agents in patients with type 2 diabetes

How to obtain appropriate type 2 diabetes control in the first 180 days of treatment initiation

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Latest News